12 Dec, 2017, 07:00 ET
RESEARCH TRIANGLE PARK, N.C. and TORONTO, Dec. 12, 2017 /PRNewswire/ -- Analytics 4 Life, a digital health company applying the power of artificial intelligence to develop solutions that improve existing care pathways, today announced that it has been named by FierceMedTech as one of 2017's Fierce 15 medtech companies, designating it as one of the most promising private medtech companies in the industry.
Analytics 4 Life's innovative technology combines artificial intelligence, cloud computing, and digital technologies to develop a proprietary approach to cardiac imaging, Phase Space Tomography™. The first application of this technology is CorVista™, a physician-directed diagnostic test that aims to assist in identifying the presence of coronary artery disease (CAD) without the use of radiation, cardiac stress, contrast agents, or patient fasting. CorVista is currently undergoing a clinical study at 13 sites in the U.S. to support algorithm development and regulatory filings. The ongoing Coronary Artery Disease Learning and Algorithm Development (CADLAD) clinical study, with more than 2,500 patients enrolled to date, will measure the performance of a machine-learned algorithm for CAD detection. Positive preliminary results from the company's CADLAD study were presented in October of this year at the Transcatheter Cardiovascular Therapeutics (TCT) conference in Denver.
"Analytics 4 Life is honored to be recognized as one of the most innovative medtech companies selected for this year's FierceMedTech Fierce 15," said Don Crawford, Analytics 4 Life chief executive officer. "We're proud to pioneer Phase Space Tomography, and are looking forward to working closely with the FDA to bring this game-changing technology to the millions of people affected by CAD."
An internationally recognized daily report reaching a network of over 90,000 medtech industry professionals, FierceMedTech provides subscribers with an authoritative analysis of the day's top stories. Every year FierceMedTech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
FierceMedTech keeps biopharma executives, device developers, engineers, and researchers updated on the must-know news, trends and developments in medical devices and diagnostics. More than 90,000 top industry professionals rely on FierceMedTech for an insider briefing on the day's top stories.
About Coronary Artery Disease
Coronary Artery Disease (CAD) is when the heart becomes weakened from a deficient supply of oxygenated blood due to a buildup of plaque in the coronary arteries, which can lead to blood clots, chest pain, and cardiac arrest. CAD affects approximately 15.5 million Americans and is the number one cause of death in the U.S.
About Analytics 4 Life
Analytics 4 Life is pioneering digital health using artificial intelligence to develop a completely new form of medical imaging. With an initial focus on coronary artery disease (CAD), Analytics 4 Life is advancing a novel, radiation-free, and exercise-free cardiac imaging technology aimed at improving existing care pathways. Analytics 4 Life is based in Toronto with U.S. headquarters in Research Triangle Park, NC. For more information, visit www.analytics4life.com.
SOURCE Analytics 4 Life
Share this article